CD44 and breast carcinoma: The structural properties of DOX@FNPs, including size, shape, stability in physiological environments, targeting activity of HA, as well as redox responsivity of cys, were found to make the nanoformulation an ideal candidate for DOX-based breast cancer treatment, increasing the cytotoxic effect of the drug by targeting CD44 protein both in 2D and 3D.